ライフサイエンスコーパス: coronary revascularization

1 hospitalization for unstable angina, or any coronary revascularization).

2 ssion for acute coronary syndrome, or repeat coronary revascularization).

3 CHD death, and hospitalization for angina or coronary revascularization).

4 h, nonfatal myocardial infarction or stroke, coronary revascularization).

5 .9% death, 1.8% myocardial infarction, 18.9% coronary revascularization).

6 ident CHD (myocardial infarction, angina, or coronary revascularization).

7 orted CHD (previous myocardial infarction or coronary revascularization).

8 MIs, and 154 hospitalizations for angina or coronary revascularizations).

9 for secondary prevention after percutaneous coronary revascularization.

10 on of the appropriate use criteria (AUC) for coronary revascularization.

11 rval, 1.01-1.65) were more likely to receive coronary revascularization.

12 than 136 kg (200 lb), and had no history of coronary revascularization.

13 versus 2.6% of those receiving UC underwent coronary revascularization.

14 mined using the Appropriate Use Criteria for coronary revascularization.

15 ator implantation can improve outcomes after coronary revascularization.

16 of coronary death, myocardial infarction, or coronary revascularization.

17 al or nonfatal myocardial infarction (MI) or coronary revascularization.

18 iagnosis of myocardial infarction (MI) after coronary revascularization.

19 t ischemia with rehospitalization, or urgent coronary revascularization.

20 oke, hospitalization for unstable angina, or coronary revascularization.

21 350 surgical patients who had not undergone coronary revascularization.

22 published joint appropriateness criteria for coronary revascularization.

23 in 69% who had an appropriate indication for coronary revascularization.

24 graphy promptly with the intent to carry out coronary revascularization.

25 he primary end point was freedom from repeat coronary revascularization.

26 an indispensable tool for decision making in coronary revascularization.

27 cated using the appropriate use criteria for coronary revascularization.

28 ization for angina, resuscitated arrest, and coronary revascularization.

29 ypass continues to be a useful technique for coronary revascularization.

30 and outcomes largely reflected the need for coronary revascularization.

31 for the use of cardiac stress imaging after coronary revascularization.

32 cardial infarction, and three (7%) underwent coronary revascularization.

33 g to whether patients had undergone previous coronary revascularization.

34 suscitation after sudden cardiac arrest, and coronary revascularization.

35 ischemia reduction with OMT with or without coronary revascularization.

36 ity, hospitalization for AMI, and subsequent coronary revascularization.

37 rization services are less likely to receive coronary revascularization.

38 ed with increasing population-based rates of coronary revascularization.

39 ardiac catheterization and history of ACS or coronary revascularization.

40 ibrillating device; 2640 (31%) had undergone coronary revascularization.

41 th refractory angina who were ineligible for coronary revascularization.

42 composite of all-cause death, MI, stroke, or coronary revascularization.

43 ercutaneous coronary interventions (PCI) for coronary revascularization.

44 o benefited from random assignment to prompt coronary revascularization.

45 .5%) patients, of whom 1253 (64.2%) received coronary revascularization.

46 ar events who might also benefit from prompt coronary revascularization.

47 using the 2012 Appropriate Use Criteria for Coronary Revascularization.

48 4.5 years), while 23 patients underwent late coronary revascularization.

49 , hospital admission for unstable angina, or coronary revascularization.

50 ncluded claims for myocardial infarction and coronary revascularization.

51 cluded all-cause death, unstable angina, and coronary revascularization.

52 of subsequent events in patients undergoing coronary revascularization.

53 oke, hospitalization for unstable angina, or coronary revascularization.

54 iovascular death, myocardial infarction, and coronary revascularization.

55 ed with lower rates of death, MI, and repeat coronary revascularization.

56 rtality, nonfatal ACS, stroke, and unplanned coronary revascularization.

57 0-day events and the need for posttransplant coronary revascularization.

58 de Inpatient Sample, which reports inpatient coronary revascularizations.

59 ce interval, -0.008% to 0.002%; P=0.705) and coronary revascularization (-0.02%; 95% confidence inter

60 Among T2MI2007, 6.3% of patients received coronary revascularization, 22% dual-antiplatelet therap

61 was lower for minimally invasive surgery for coronary revascularization (-$30,850; 95% CI, -$31,629 t

62 42.2 +/- 9.6% vs. 38.6 +/- 9.1%, p = 0.001), coronary revascularization (41.2 +/- 9.3% vs. 38.1 +/- 9

63 ified 23 033 dialysis patients who underwent coronary revascularization (6178 coronary artery bypass

64 11.4 patients/100 person-years; P<0.001) and coronary revascularization (8.8 vs 3.2 patients/100 pers

65 less likely to receive primary percutaneous coronary revascularization (84% versus 79% with HF, P<0.

66 d for chest pain; there were no instances of coronary revascularization, ACS, or death (0% for all; 9

67 ion for unstable angina, or urgent/emergency coronary revascularization)-actively surveyed for 1 year

68 Cardiac catheterization, coronary revascularization, acute myocardial infarction,

69 ced among 210 cTn- patients undergoing early coronary revascularization (adjusted hazard ratio, 0.61;

70 Racial differences in the use of coronary revascularization after acute myocardial infarc

71 nformation on rates and predictors of repeat coronary revascularization after CABG in the modern era.

72 fective compared with the strategy of prompt coronary revascularization among patients identified a p

73 re the timing, frequency, and type of repeat coronary revascularization among patients receiving BIMA

74 trated a significant reduction in subsequent coronary revascularization among patients with stable an

75 dical therapy compared with 24.8% for prompt coronary revascularization among the 381 coronary artery

76 all patients, risk-adjusted rates of 30-day coronary revascularization and 1-year mortality.

77 November 1, 2004, and June 30, 2007, who had coronary revascularization and an index cardiac outpatie

78 r burden of inducible ischemia, a history of coronary revascularization and current anxiety and depre

79 lacks are less likely than whites to receive coronary revascularization and evidence-based therapies

80 They were less likely to undergo coronary revascularization and had longer duration of ho

81 the 2009 Appropriate Use Criteria (AUC) for Coronary Revascularization and in-hospital mortality, bl

82 herapy and with a strategy of prompt initial coronary revascularization and intensive medical therapy

83 AKI is common after multivessel coronary revascularization and is more likely after CABG

84 Clinical outcomes between coronary revascularization and medical treatment without

85 in death or acute coronary syndrome between coronary revascularization and no revascularization in t

86 more aggressive intensive medical therapy or coronary revascularization and optimum medical therapy.

87 s to assess the current state of robotics in coronary revascularization and to consider what advances

88 indications and patient selection for hybrid coronary revascularization and to outline current techni

89 likely to be admitted to hospitals offering coronary revascularization and to undergo early revascul

90 er acute myocardial infarction for unplanned coronary revascularization and unstable angina (UA) are

91 farction, other hospitalizations for CHD and coronary revascularization) and quantitative measures of

92 ive CAD (history of myocardial infarction or coronary revascularization) and without documented contr

93 ts of myocardial infarction hospitalization, coronary revascularization, and all-cause mortality.

94 e of myocardial infarction, ischemic stroke, coronary revascularization, and cardiovascular death).

95 was the composite of myocardial infarction, coronary revascularization, and death from any cause.

96 rials: death, myocardial infarction, stroke, coronary revascularization, and hospitalization for angi

97 (MACE: death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unst

98 dress the expanding clinical indications for coronary revascularization, and in an effort to align th

99 ction, coronary heart disease death, stroke, coronary revascularization, and incident HF.

100 s were a history of diabetes, heart failure, coronary revascularization, and larger hospital size.

101 dex, total number of coronary lesions, prior coronary revascularization, and left ventricular ejectio

102 To compare rates of hospital transfer, coronary revascularization, and mortality after AMI for

103 ardial infarction, an increased incidence of coronary revascularization, and no effect in all-cause m

104 on of AMI, elective percutaneous or surgical coronary revascularization, and other cardiovascular sur

105 erosclerosis risk factors, coronary calcium, coronary revascularization, and peripheral vascular dise

106 rdial infarctions, 265 ischemic strokes, 628 coronary revascularizations, and 163 cardiovascular deat

107 of ESRD, CHD, stroke, and combined CVD (CHD, coronary revascularization, angina, stroke, heart failur

108 cluding robotic-assisted surgery; and hybrid coronary revascularization are discussed.

109 tion strategy, and ways to prevent AKI after coronary revascularization are needed.

110 To determine whether a strategy of prompt coronary revascularization as compared with an initial s

111 Lower utilization of elective coronary revascularization, aspirin, and glycoprotein II

112 The rate of repeat coronary revascularization at 1 year was 1.4% in the off

113 lization for evaluation of possible AMI, and coronary revascularization at 30 days.

114 275 consecutive patients undergoing surgical coronary revascularization at Duke between January 1, 19

115 The appropriateness for coronary revascularization at the time of coronary angio

116 In prior coronary revascularization AUC documents, indications fo

117 As seen with the prior coronary revascularization AUC, revascularization in cli

118 rivate insurance were more likely to receive coronary revascularization before and after reform.

119 comes in all diabetic patients who underwent coronary revascularization between 2007 and 2014 (n = 4,

120 rdance in assessments of appropriateness for coronary revascularization between physicians and the AU

121 first CHD event (acute coronary syndrome or coronary revascularization) between 2000 and 2008 in an

122 y injury (AKI) is a known complication after coronary revascularization, but few studies have directl

123 cardiac death is deferred for 90 days after coronary revascularization, but mortality may be highest

124 scular events by 27% and the need for repeat coronary revascularization by 30%, compared with less in

125 core by 1 U increased the odds of subsequent coronary revascularization by 5.70 times (95% confidence

126 Coronary revascularization by CABG compared with PCI is

127 iles to compare the practice and outcomes of coronary revascularization (by either percutaneous coron

128 Annual procedure rates of coronary revascularizations, CABG surgery, and PCI.

129 h more extensive CAD in whom a more complete coronary revascularization can be achieved with CABG hav

130 placebo, 1.5%; HR, 0.77 [95% CI, 0.34-1.76]; coronary revascularization: chelation, 15%; placebo, 18%

131 predicted outcomes and the effectiveness of coronary revascularization compared with medical therapy

132 dent myocardial infarction, definite angina, coronary revascularization (coronary artery bypass graft

133 incident CVD events (myocardial infarction, coronary revascularization, coronary death, or stroke) d

134 Among CKD patients undergoing coronary revascularization, death is more frequent than

135 Coronary revascularization decisions for patients with C

136 t ischemia with rehospitalization, or urgent coronary revascularization during index hospitalization)

137 eous coronary intervention (MS-PCI) complete coronary revascularization during the index hospitalizat

138 OMT was underused in patients treated with coronary revascularization, especially CABG.

139 ac surgery on myocardial infarction (MI) and coronary revascularization following coronary stenting.

140 free from any myocardial infarction (MI) or coronary revascularization for >1 year at inclusion.

141 institutions assessed the appropriateness of coronary revascularization for 68 indications that had b

142 rt disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and

143 ary heart disease (CHD) death, MI, or urgent coronary revascularization for myocardial ischemia.

144 y selected cTn+ patients who underwent early coronary revascularization for obstructive coronary arte

145 eral, as seen with the prior AUC, the use of coronary revascularization for patients with acute coron

146 In general, the use of coronary revascularization for patients with acute coron

147 e relative benefit of medical therapy versus coronary revascularization for reducing ischemia is unkn

148 ns face in determining the optimal method of coronary revascularization for this high-risk population

149 te of the appropriate use criteria (AUC) for coronary revascularization frequently considered.

150 acetylcysteine, sodium bicarbonate, off-pump coronary revascularization, goal-directed hemodynamic th

151 een the intensive medical therapy and prompt coronary revascularization groups were seen in any risk

152 able angina [UA] leading to hospitalization, coronary revascularization >/=30 days post-randomization

153 ted outpatients with stable CAD (i.e., MI or coronary revascularization >1 year previously).

154 unstable angina requiring rehospitalization, coronary revascularization (>/=30 days after randomizati

155 of mortality, myocardial infarction, or late coronary revascularization (>/=90 days after CCTA) were

156 2.45; 95% CI, 1.98-3.03; P < .001), whereas coronary revascularization had a negative relationship w

157 Use of cardioprotective medication after coronary revascularization has been inconsistent and rel

158 AUC for coronary revascularization have been developed by select

159 Although appropriate use criteria for coronary revascularization have been developed to improv

160 terval, 0.50 to 0.93), including the risk of coronary revascularization (hazard ratio, 0.56, 95% conf

161 detector CT group was less likely to undergo coronary revascularization (hazard ratio, 0.76; 95% CI:

162 Hybrid coronary revascularization (HCR) combines arterial coron

163 Hybrid coronary revascularization (HCR) combines minimally inva

164 Hybrid coronary revascularization (HCR) involves a combination

165 events, hemorrhagic stroke, ischemic stroke, coronary revascularization, heart failure, total mortali

166 The clinical significance of incomplete coronary revascularization (ICR) after percutaneous coro

167 lication of the Appropriate Use Criteria for Coronary Revascularization in 2009, there have been sign

168 xamine temporal trends in the utilization of coronary revascularization in a geographically defined p

169 uidelines, which emphasize a primary role of coronary revascularization in acute coronary syndromes.

170 on myocardial infarction patients undergoing coronary revascularization in an 8-hospital network were

171 BG may be preferred over PCI for multivessel coronary revascularization in appropriately selected pat

172 re, high blood urea nitrogen, and history of coronary revascularization in both data sets (all P<0.05

173 the pattern of cardiac stress testing after coronary revascularization in community practice.

174 tial underutilization and overutilization of coronary revascularization in contemporary clinical prac

175 ing Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice (COMPARE) t

176 ed with increasing population-based rates of coronary revascularization in Medicare beneficiaries.

177 The study assessed the appropriateness of coronary revascularization in Ontario, Canada, and exami

178 Further adjustment for coronary revascularization in our models significantly a

179 of clarity exists about the role of complete coronary revascularization in patients presenting with n

180 ronary artery disease may worsen and require coronary revascularization in patients with risk factors

181 t intensive medical therapy is comparable to coronary revascularization in suppressing ischemia and p

182 ents undergoing surgical versus percutaneous coronary revascularization in the era of drug-eluting st

183 of typical "real-world" patients undergoing coronary revascularization in the modern era.

184 e is wide geographic variation in the use of coronary revascularization in the United States.

185 There were no deaths, AMIs, or coronary revascularizations in either group.

186 after a CHD event (myocardial infarction or coronary revascularization) in 2007, 2008, or 2009.

187 farction, angina with > or =50% stenosis, or coronary revascularization) in men under age 46 years or

188 Among dialysis patients undergoing coronary revascularization, in-hospital mortality was hi

189 inical outcomes with the use of FFR to guide coronary revascularization, including a reduction in car

190 Both intensive medical therapy and coronary revascularization induced significant but compa

191 Coronary revascularization is among the most common hosp

192 Coronary revascularization is an effective means of trea

193 Underutilization of coronary revascularization is associated with significan

194 review of common clinical scenarios in which coronary revascularization is frequently considered.

195 nvasive treatment strategy, in which routine coronary revascularization is performed, or a conservati

196 One-stop hybrid coronary revascularization is reasonable, safe, and feas

197 se in high-risk patients undergoing surgical coronary revascularization is still a matter of debate.

198 ardial infarction patients, complete 1-stage coronary revascularization is superior to multistage PCI

199 heart disease, but the optimal strategy for coronary revascularization is unknown.

200 arction (kappa, 0.71-0.74) and excellent for coronary revascularization (kappa, 0.88-0.91).

201 nt of fractional flow reserve (FFR) to guide coronary revascularization lags despite robust supportiv

202 ores in the mid-range (4 to 6) indicate that coronary revascularization may be appropriate for the cl

203 missing significantly fewer days of work for coronary revascularization (mean difference, -37.7 days;

204 priate role of elective stress testing after coronary revascularization, more than one half of all pa

205 ry heart disease or cerebrovascular disease, coronary revascularization, myocardial infarction, and s

206 ith regard to invasive coronary angiography, coronary revascularization, nonfatal myocardial infarcti

207 s significantly associated with a history of coronary revascularization (odds ratio 2.24, 95% confide

208 terval, 0.95-1.84; P=0.09) and higher use of coronary revascularizations (odds ratio, 1.77; 95% confi

209 s coronary intervention in the guidelines on coronary revascularization of the European Society of Ca

210 ysis was performed to evaluate the effect of coronary revascularization on event-free survival.

211 arious imaging modalities, and the impact of coronary revascularization on outcome.

212 l myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular

213 hock remains unacceptably high despite early coronary revascularization or other therapies.

214 first-ever CHD event (myocardial infarction, coronary revascularization, or cardiovascular death) or

215 infarction, nonfatal cerebrovascular event, coronary revascularization, or cardiovascular death) ove

216 ardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death).

217 nfatal myocardial infarction (MI) or stroke, coronary revascularization, or cardiovascular death, ass

218 infarction, nonfatal cerebrovascular event, coronary revascularization, or cardiovascular deaths).

219 ular outcomes (death, myocardial infarction, coronary revascularization, or cerebrovascular events) i

220 nary syndrome without myocardial infarction, coronary revascularization, or CHD death.

221 oronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart

222 stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in

223 mary end point (death, reinfarction, stroke, coronary revascularization, or hospitalization for angin

224 s time to total death, recurrent MI, stroke, coronary revascularization, or hospitalization for angin

225 te of total mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angin

226 bined primary endpoint of death, MI, stroke, coronary revascularization, or hospitalization for angin

227 ity,recurrent myocardial infarction, stroke, coronary revascularization, or hospitalization for angin

228 , acute MI or other acute coronary syndrome, coronary revascularization, or stroke) associated with t

229 ular causes, nonfatal myocardial infarction, coronary revascularization, or stroke, assessed 12 month

230 ve influenced the volume and distribution of coronary revascularizations over the past decade.

231 ntensive medical therapy versus 27.1% prompt coronary revascularization; P=0.010; hazard ratio=2.10;

232 igher early compared to late mortality after coronary revascularization, particularly after PCI.

233 on (PCI) for patients undergoing multivessel coronary revascularization-particularly among patients w

234 efinition for "clinically relevant MI" after coronary revascularization (PCI or CABG), which is appli

235 ng clopidogrel >12 months after percutaneous coronary revascularization (PCI).

236 ents with type 2 diabetes mellitus to prompt coronary revascularization plus intensive medical therap

237 Recurrent MI, CHD events (recurrent MI or a coronary revascularization procedure), and mortality wer

238 fies all Medicare beneficiaries undergoing a coronary revascularization procedure: coronary artery by

239 nts is currently the most commonly performed coronary revascularization procedure; hence, optimizing

240 P=0.009) and required a higher rate of late coronary revascularization procedures (PCI: Mod-CAD vs.

241 healthcare reform in Massachusetts on use of coronary revascularization procedures and in-hospital an

242 tory to maximal medical therapy and standard coronary revascularization procedures are diagnosed each

243 Reducing insurance barriers to receipt of coronary revascularization procedures has not yet elimin

244 onary artery disease, and that many elective coronary revascularization procedures may be unnecessary

245 on the trends in the volume and outcomes of coronary revascularization procedures performed on Medic

246 0.5 mg/d was due primarily to lower risks of coronary revascularization procedures, hospitalization f

247 rimary composite outcome, the rate of repeat coronary revascularization, quality of life, or neurocog

248 among 1,314 patients undergoing percutaneous coronary revascularization randomized to either PES (N =

249 he spectrum of surgical procedures in hybrid coronary revascularization ranges from left internal mam

250 ital claims data, we compared differences in coronary revascularization rates (coronary artery bypass

251 between coronary angiography rates and total coronary revascularization rates was strong (R(2)=0.84).

252 of cardiac death, myocardial infarction, or coronary revascularization related to the target SVG dur

253 ng all Medicare beneficiaries undergoing any coronary revascularization remained between 2.1% and 2.2

254 eral studies in patients undergoing surgical coronary revascularization report reduced release of cre

255 95% CI: 0.68 to 0.90; p = 0.001), and repeat coronary revascularization (RR: 0.74, 95% CI: 0.65 to 0.

256 ients admitted to hospitals with and without coronary revascularization services are less likely to r

257 more patients with significant CAD requiring coronary revascularization, shorten hospital stay, or al

258 Coronary revascularization should be reserved for those

259 Prompt coronary revascularization significantly increases costs

260 imus-Eluting Stent with a Standard Stent for Coronary Revascularization], SIRIUS [SIRolImUS-coated Bx

261 rebrovascular events of 2 different complete coronary revascularization strategies in patients with n

262 ll future comparative studies of comparative coronary revascularization strategies.

263 diabetes mellitus is increasing, the optimal coronary revascularization strategy in diabetic patients

264 This study sought to determine the optimal coronary revascularization strategy in patients with dia

265 reserve (FFR) on the reclassification of the coronary revascularization strategy on individual patien

266 for AKI should be considered when choosing a coronary revascularization strategy, and ways to prevent

267 Regardless of coronary revascularization strategy, medication adherenc

268 ath, myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic a

269 ehospitalization for unstable angina, repeat coronary revascularization (target vessel revascularizat

270 er rates of major adverse cardiac events and coronary revascularization than those with normal MPI.

271 Blacks had 30% lower odds of receiving coronary revascularization than whites in the prereform

272 Among the Medicare population undergoing coronary revascularization, the introduction of drug-elu

273 ispensed during the first year after initial coronary revascularization to identify patients who neve

274 utilize robotic telemanipulation to perform coronary revascularization via limited access.

275 The hazard ratio for coronary revascularization was 1.09 (95% confidence inte

276 The rate of coronary revascularization was 54% in the uncertain cate

277 Coronary revascularization was associated with a lower a

278 coronary artery bypass graft surgery, prompt coronary revascularization was associated with a signifi

279 sis of 143 individuals with cTn+ AHFS, early coronary revascularization was associated with reduced m

280 Prompt coronary revascularization was associated with small yet

281 ysis of patients undergoing first documented coronary revascularization was conducted using 2 complem

282 The overall rate of coronary revascularization was low in both groups: 31 (5

283 5% decrease (P < .001) in the annual rate of coronary revascularizations was observed from 2001-2002

284 e sex, coexisting hypertension, and a recent coronary revascularization were associated with statin t

285 Appropriate Use Criteria for Coronary Revascularization were developed to critically

286 plants and those who underwent pretransplant coronary revascularization were excluded.

287 gender, previous myocardial infarction, and coronary revascularization were most strongly correlated

288 of diagnostic testing, medical therapy, and coronary revascularization were seen among patients trea

289 iac events (death, myocardial infarction, or coronary revascularization), were assessed at 30 days by

290 nical scenario for which the likelihood that coronary revascularization will improve health outcomes

291 revascularization compared with percutaneous coronary revascularization with drug-eluting stents (DES

292 on maintenance dialysis who received initial coronary revascularization with either coronary artery b

293 utcomes and may predict the effectiveness of coronary revascularization with either coronary artery b

294 r severe recurrent ischemia requiring urgent coronary revascularization with the principal analysis s

295 sis codes for acute myocardial infarction or coronary revascularization with WHI outcomes adjudicated

296 primary endpoint (22 [9%] patients underwent coronary revascularization within 30 days in the CCTA gr

297 -matched analysis, we examined whether early coronary revascularization (within 14 days of emergency

298 A principal benefit of surgical coronary revascularization without cardiopulmonary bypas

299 asive coronary surgery is totally endoscopic coronary revascularization without utilization of cardio

300 nical scenario for which the likelihood that coronary revascularization would improve health outcomes